Increasing to weekly adalimumab dosing leads to improved psoriasis outcomes-A retrospective single-centre review of real-world data

J Eur Acad Dermatol Venereol. 2023 Apr;37(4):e527-e528. doi: 10.1111/jdv.18623. Epub 2022 Oct 10.

Authors

Amaani B Hussain^{1

2}, Alison Havelin¹, Stephanie Ball¹, Sophie Weatherhead¹, Nick J Reynolds^{1

2}, Philip Hampton¹

Affiliations

¹ Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
² Translational and Clinical Research Institute (Dermatology), Newcastle University, Newcastle upon Tyne, UK.

PMID: 36178145
DOI: 10.1111/jdv.18623

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / therapeutic use
Antibodies, Monoclonal, Humanized
Etanercept
Humans
Psoriasis* / drug therapy
Retrospective Studies
Treatment Outcome

Substances

Adalimumab
Antibodies, Monoclonal, Humanized
Etanercept